Aprea Therapeutics, Inc. (APRE)

The past six months have seen several events impacting Aprea Therapeutics' stock price, including private placements, clinical trial updates, financial results and corporate updates, an executive appointment, patent protection, and stock price performance. The company announced an oversubscribed $30 million private placement on March 30, 2026, which closed on April 1, 2026, following earlier private placements of $5.6 million in January 2026 and $3.1 million in December 2025. On March 30, 2026, Aprea Therapeutics highlighted positive emerging clinical activity for its WEE1 inhibitor, APR-1051, including a confirmed partial response in the ongoing Phase 1 ACESOT-1051 trial. The company reported its Fourth Quarter and Full Year 2025 Financial Results and provided a corporate update on March 16, 2026. In February 2026, Aprea Therapeutics appointed Eugene Kennedy as Chief Medical Advisor and expanded its global patent protection to strengthen its DDR oncology pipeline. The share price declined by 52.65% between April 10, 2025, and April 9, 2026.

As a clinical-stage biopharmaceutical company, Aprea Therapeutics, Inc. does not currently have commercialized products or services, so there is no information available regarding demand seasonality for its products or services.

Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on precision oncology, developing targeted therapies for patients with biomarker-defined cancers. The company is dedicated to discovering and developing novel cancer therapeutics that exploit vulnerabilities associated with cancer cell mutations, aiming to kill tumors while minimizing harm to healthy tissues. The company's work primarily centers on solid tumor indications and cancers characterized by defects in DNA damage response (DDR) pathways. Aprea Therapeutics' major product candidates include APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase, currently in Phase 1 clinical trials for advanced solid tumors with biomarkers, and ATRN-119 (Mosipasertib), a novel macrocyclic ATR inhibitor, which is an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related (ATR) kinase, currently in Phase 1/2a clinical trials for solid tumor indications. The company also has an early-stage program in the lead optimization stage for an undisclosed DDR target.

Aprea Therapeutics, Inc. is headquartered in Doylestown, Pennsylvania, United States. As a clinical-stage biopharmaceutical company, its primary operations are focused on research and development, with clinical trials conducted in various locations.

Information specifically detailing Aprea Therapeutics' brand reputation in the past year is not readily available in the provided search results. The company's communications primarily focus on scientific advancements, clinical trial progress, and financial updates. Events that could be perceived as impacting reputation are generally related to clinical trial outcomes, financial stability, and strategic corporate decisions.

Aprea Therapeutics, Inc. has 27 institutional owners and shareholders, holding a total of 1,695,512 shares, representing 34.19% of the company's stock. Major institutional owners include AIGH Capital Management LLC, Murchinson Ltd., Sphera Funds Management Ltd., Nantahala Capital Management, LLC, DRW Securities, LLC, Morgan Stanley, Vanguard Group Inc, Citadel Advisors Llc, Jane Street Group, Llc, and Geode Capital Management, Llc.